Can a natural antibody quiet inflammation? a new trial investigates

NCT ID NCT05099510

Completed Knowledge-focused Sponsor: XBiotech, Inc. Source: ClinicalTrials.gov ↗

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This early-stage trial is testing whether Natrunix, an antibody that targets a key inflammatory protein called IL-1-alpha, is safe and how it behaves in the body. About 24 healthy adults will receive either Natrunix or a placebo via injection, with doses increasing across groups. Researchers will monitor for side effects and measure drug levels in the blood over a month. The goal is to gather essential safety data before exploring its potential for treating inflammatory diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Natrunix (XB2001), a recombinant human monoclonal antibody that targets interleukin-1-alpha
What this could lead to: If safe and well-tolerated, Natrunix could become a treatment for inflammatory conditions driven by IL-1-alpha.
What could go wrong: This is an early, small study focused on safety, not effectiveness. Side effects or unexpected reactions may occur, and results may not predict success in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PHARMACOKINETICS

Contacts and locations

Locations

BioBehavioral Research of Austin, A Telemed2U Company

Austin, Texas, 78759, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.